NCT04695405 is a clinical trial of Saliva Genetic Samples in Treatment Resistant Depression, sponsored by Brain and Cognition Discovery Foundation.

Who is sponsoring NCT04695405?

NCT04695405 is sponsored by Brain and Cognition Discovery Foundation.

What drugs are being tested in NCT04695405?

Interventions in NCT04695405: Saliva Genetic Samples.

What condition does NCT04695405 study?

NCT04695405 studies Treatment Resistant Depression.

Is NCT04695405 still recruiting?

NCT04695405 is currently completed. Last updated 18 August 2021.

Last reviewed 2021-08-18 · How we verify

NCT04695405

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacogenetics Associated With IV Ketamine

Completed Last updated 18 August 2021

What this trial tests

trial testing Saliva Genetic Samples in Treatment Resistant Depression in 85 participants. Completed in 2 July 2021.

Timeline

21 January 2021

Primary endpoint
2 July 2021

2 July 2021

Quick facts

Lead sponsor	Brain and Cognition Discovery Foundation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	85
Start date	21 January 2021
Primary completion	2 July 2021
Estimated completion	2 July 2021
Sites	1 location across Canada

Drugs / interventions tested

Saliva Genetic Samples

Conditions studied

Treatment Resistant Depression — all drugs for Treatment Resistant Depression →

Sponsor

Brain and Cognition Discovery Foundation

Who can join

Adults 18 to 65, any sex, with Treatment Resistant Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from treatment resistant depression. Patients who have received IV ketamine at the clinic are eligible to participate in this study where genetic biomarkers are correlated with response to IV ketamine.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression.
Rodrigues NB, Chen-Li D, Di Vincenzo JD, Juneja A, et al · · 2024 · cited 7× · PMID 38477185 · DOI 10.1177/02698811241238284
The Influence of Childhood Trauma on the Real‐World Effectiveness of Ketamine in Adults With Treatment‐Resistant Depression
Johnson D, Rodrigues N, Mansur R, McIntyre R, et al · · 2025

Verify or expand the search:

Other recruiting trials for Treatment Resistant Depression

Currently open trials in the same condition.

NCT07183748 — Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression · Phase 2 · recruiting
NCT06938841 — Maintenance rTMS for Depression (Maitr-De) · NA · recruiting
NCT06236711 — Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD) · NA · active not recruiting
NCT05774665 — Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression · Phase 2 · active not recruiting
NCT06895863 — COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression · NA · recruiting

Other Brain and Cognition Discovery Foundation trials

Trials by the same sponsor.

NCT05029466 — Psilocybin for Treatment-Resistant Depression · Phase 2 · completed
NCT05047952 — Vortioxetine for Post-COVID-19 Condition · Phase 2 · completed
NCT04209296 — Chart Review of Patients Undergoing Ketamine Infusions · completed
NCT03939676 — Evaluating Motivation and Reward Mechanisms and Brain Substrates in Adults With Obesity · completed
NCT03999567 — Validation Study: Mobile DSST on Cognition in Adults With MDD · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04695405 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brain and Cognition Discovery Foundation
Last refreshed: 18 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04695405.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing